ARQT vs. ETNB, TYRA, TNGX, OPK, SPRY, IMNM, ELVN, SAVA, ZNTL, and SAGE
Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include 89bio (ETNB), Tyra Biosciences (TYRA), Tango Therapeutics (TNGX), OPKO Health (OPK), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Enliven Therapeutics (ELVN), Cassava Sciences (SAVA), Zentalis Pharmaceuticals (ZNTL), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
89bio has higher earnings, but lower revenue than Arcutis Biotherapeutics. 89bio is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
89bio received 43 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 62.09% of users gave 89bio an outperform vote while only 61.18% of users gave Arcutis Biotherapeutics an outperform vote.
In the previous week, 89bio had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for 89bio and 6 mentions for Arcutis Biotherapeutics. 89bio's average media sentiment score of 0.88 beat Arcutis Biotherapeutics' score of 0.49 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
89bio has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
89bio has a net margin of 0.00% compared to 89bio's net margin of -439.79%. Arcutis Biotherapeutics' return on equity of -31.01% beat 89bio's return on equity.
89bio presently has a consensus price target of $29.00, indicating a potential upside of 251.09%. Arcutis Biotherapeutics has a consensus price target of $26.56, indicating a potential upside of 213.52%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe 89bio is more favorable than Arcutis Biotherapeutics.
Summary
89bio beats Arcutis Biotherapeutics on 9 of the 15 factors compared between the two stocks.
Get Arcutis Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcutis Biotherapeutics Competitors List
Related Companies and Tools
